Table I.
Gene | Treatments
|
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
4°C | 40°C | Darkness | Wounding | −Water | +NaCl | +Polyethylene glycol (PEG) | |||||||
AtSK11 | 0 | 0 | − (2) | 0 | 0 | 0 | 0 | ||||||
AtSK12 | 0 | 0 | − (5) | 0 | 0 | 0 | 0 | ||||||
AtSK13 | 0 | 0 | 0 | 0 | + (2) | + (3) | + (4) | ||||||
AtSK21 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
AtSK22 | 0 | 0 | − (2) | 0 | 0 | 0 | 0 | ||||||
AtSK23 | 0 | 0 | − (3) | 0 | 0 | 0 | 0 | ||||||
AtSK31 | 0 | 0 | + (4) | 0 | 0 | + (2) | + (2.5) | ||||||
AtSK32 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
AtSK41 | 0 | 0 | − (4) | 0 | 0 | 0 | 0 | ||||||
AtSK42 | 0 | 0 | − (4) | 0 | 0 | + (2.5) | + (2) | ||||||
AtMAP3Kε1 | 0 | 0 | − (4) | 0 | 0 | 0 | 0 | ||||||
AtMAP3Kε2 | 0 | 0 | − (4) | 0 | 0 | 0 | 0 | ||||||
AtMAP4Kα1 | 0 | 0 | − (2) | + (3) | 0 | + (7) | + (6.5) | ||||||
AtMAP4Kα2 | 0 | 0 | − (2) | 0 | 0 | 0 | + (2) | ||||||
MEA | + (2.5) | 0 | + (8) | 0 | 0 | 0 | 0 | ||||||
SUP | 0 | 0 | 0 | 0 | 0 | + (2) | + (3) | ||||||
AS1 | 0 | 0 | − (3) | 0 | 0 | + (2) | + (2) | ||||||
SCR | 0 | − (2) | − (8) | 0 | 0 | 0 | 0 | ||||||
Ats1A | − (2) | − (2) | − (100) | 0 | − (2) | + (2.5) | − (4) | ||||||
RD29A | + (36) | + (100) | − (25) | 0 | + (56) | + (35) | + (30) |
This table presents the increase or decrease rates of the transcript levels during the treatment kinetics, compared with the T0 value. 0, Variation less than 2-fold. +, Increase; –, decrease; (n), n-fold increase or decrease. More than 2-fold variations are shown in bold. Variations concerning very low expressed genes, such as SUP, may not be significant.